Clinical Trials Directory

Trials / Completed

CompletedNCT03594877

Effect of Sublimated Mare Milk Supplement on Gut Microbiome in Psoriasis Patients

Effectiveness of the Sublimated Mare Milk on the Gut Microbiome in Psoriasis and Healthy Patients

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
40 (actual)
Sponsor
Nazarbayev University Medical Center · Academic / Other
Sex
All
Age
30 Years – 45 Years
Healthy volunteers
Accepted

Summary

This study evaluates the effect of dietary supplement consisting of sublimated mare milk on intestinal microbiota among psoriasis and healthy participants.

Detailed description

The gut microbiome is believed to play an important role in the immune system regulation, since intestines are the largest lymphoid organ in a human body. Deviations from healthy composition of intestinal flora are associated with various diseases including allergy and autoimmunity. Psoriasis is the one of the long-lasting autoimmune diseases that is characterized by patches on the skin and further health complications throughout the life. However, lack of studies does not allow proper evaluation of role of gut microbiome in psoriasis patients. Therefore, potential interplay between gut microbiome and immune system in psoriasis would be studied in this clinical trial. Particularly, the investigators hypothesize that sublimated mare milk supplement can have an impact on gut immune system and gut microbiome composition in the psoriasis patients. In this trial, there will be two parallel groups: crossover psoriasis patients (standard treatment first for 3 months, next 3 months standard treatment plus sublimated mare milk supplement) and healthy volunteers group. Subsequently, association of intestinal flora with immune status will be analyzed and compared between these groups.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTSublimated mare milkThe dietary supplement mare milk product, which is obtained from fresh (few hours) through sublimation process. This product is first mixed with warm water (37-38 degrees of Celsius) and then will be given to participants.

Timeline

Start date
2018-04-01
Primary completion
2019-11-30
Completion
2020-12-30
First posted
2018-07-20
Last updated
2021-02-08

Locations

1 site across 1 country: Kazakhstan

Source: ClinicalTrials.gov record NCT03594877. Inclusion in this directory is not an endorsement.